A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab

Nivolumab, an immune checkpoint inhibitor is the first-line therapy for platinum-resistant recurrent/metastatic head and neck cancer, and highly effective for some patients. However, no factors have been identified that could predict response or prognosis after nivolumab administration. We retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuba, Kiyomi, Inoue, Hitoshi, Matsumura, Satoko, Enoki, Yuichiro, Kogashiwa, Yasunao, Ebihara, Yasuhiro, Nakahira, Mitsuhiko, Yamazaki, Tomoko, Yasuda, Masanari, Kaira, Kyoichi, Kagamu, Hiroshi, Sugasawa, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800384/
https://www.ncbi.nlm.nih.gov/pubmed/36581686
http://dx.doi.org/10.1038/s41598-022-27237-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800384/
https://www.ncbi.nlm.nih.gov/pubmed/36581686
http://dx.doi.org/10.1038/s41598-022-27237-0

Ejemplares similares